Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Peter Van Oyen"'
Autor:
Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els Everaert, Daan De Maeseneer, Michiel Strijbos, Alain Bols, Karen Fransis, Steffi Oeyen, Pieter-Jan van Dam, Gert Van den Eynden, Annemie Rutten, Markus Aly, Tobias Nordström, Steven Van Laere, Mattias Rantalainen, Prabhakar Rajan, Lars Egevad, Anders Ullén, Jeffrey Yachnin, Luc Dirix, Henrik Grönberg, Johan Lindberg
Publikováno v:
Genome Medicine, Vol 10, Iss 1, Pp 1-13 (2018)
Abstract Background There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficient
Externí odkaz:
https://doaj.org/article/4783b889dd4d4c3c8abf60a59cf0a086
Publikováno v:
Advances in Urology, Vol 2009 (2009)
A 72-year-old patient was treated in our department for an invasive bladder TCC by cystoprostatectomy with the intention to create an orthotopic neobladder. During surgery it appeared to be impossible to mobilize part of the preterminal ileum into th
Externí odkaz:
https://doaj.org/article/8ef2cb9f0b50445a8b23fae2e43ad879
Autor:
Daan De Maeseneer, Lucien Hoekx, Jean Vandebroek, Els Everaert, Alain Bols, Nick Beije, Anja Brouwer, Peter A. van Dam, Valerie van Dam, Karen Fransis, Wim Demey, Bram De Laere, Annemie Rutten, Steven Van Laere, Jozef Ampe, Stefan Sleijfer, Barbara Brouwers, Gert Van den Eynden, Steffi Oeyen, Piet Ost, Inge de Kruijff, Piet Van Kerckhove, Luc Dirix, Michiel Strijbos, Willem Lybaert, Dirk Schrijvers, Peter Van Oyen, Christophe Ghysel
Publikováno v:
The prostate
Prostate, 78(6), 435-445. Wiley-Liss Inc.
Prostate, 78(6), 435-445. Wiley-Liss Inc.
BACKGROUND The outcome to treatment administered to patients with metastatic castration-resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making. OBJECTIVE To investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194ea2a43c5cf83b8353b5b6d3b1498e
https://pure.eur.nl/en/publications/9e1136f9-8262-4d90-85e8-f9a9665f8571
https://pure.eur.nl/en/publications/9e1136f9-8262-4d90-85e8-f9a9665f8571
Autor:
Annemie Rutten, Steven Van Laere, Henrik Grönberg, Peter A. van Dam, Dirk Goossens, Daan De Maeseneer, Mattias Rantalainen, Willem Lybaert, Piet Ost, Steffi Oeyen, Jozef Ampe, Gert Van den Eynden, Jurgen Del Favero, Lien Heyrman, Michiel Strijbos, Barbara Brouwers, Anja Brouwer, Karen Fransis, Peter Van Oyen, Bram De Laere, Wim Demey, Lucien Hoekx, Stefan Sleijfer, Anders Ullén, Christophe Ghysel, Els Everaert, Prabhakar Rajan, Alain Bols, Nick Beije, Ingeborg E. de Kruijff, Jeffrey Yachnin, Markus Mayrhofer, Johan Lindberg, Valerie van Dam, Tom Whitington, Dirk Schrijvers, Luc Dirix
Publikováno v:
Clinical cancer research
CLINICAL CANCER RESEARCH
Clinical Cancer Research, 25(6), 1766-1773. American Association for Cancer Research Inc.
CLINICAL CANCER RESEARCH
Clinical Cancer Research, 25(6), 1766-1773. American Association for Cancer Research Inc.
Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line of AR signaling inhibitors (ARSi). Expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7775cd4b741e99e3013042119f7c15c7
https://hdl.handle.net/10067/1585390151162165141
https://hdl.handle.net/10067/1585390151162165141
Autor:
Peter Van Oyen, Wim Demey, Els Everaert, Steven Van Laere, Daan De Maeseneer, Gert Van den Eynden, Lars Egevad, Michiel Strijbos, Karen Fransis, Alain Bols, Johan Lindberg, Mattias Rantalainen, Willem Lybaert, Piet Ost, Annemie Rutten, Dirk Schrijvers, Tom Whitington, Anders Ullén, Barbara Brouwers, Steffi Oeyen, Luc Dirix, Markus Aly, Prabhakar Rajan, Peter A. van Dam, Lucien Hoekx, Christophe Ghysel, Jozef Ampe, Tobias Nordström, Henrik Grönberg, Bram De Laere, Jeffrey Yachnin, Markus Mayrhofer
Publikováno v:
Genome Medicine
Genome Medicine, Vol 10, Iss 1, Pp 1-13 (2018)
GENOME MEDICINE
Genome medicine
Genome Medicine, Vol 10, Iss 1, Pp 1-13 (2018)
GENOME MEDICINE
Genome medicine
BackgroundThere are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficiently acceler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11effbe8e91743dd8c5e8ad071584a0a
https://pubmed.ncbi.nlm.nih.gov/30458854
https://pubmed.ncbi.nlm.nih.gov/30458854
Autor:
Ignace Billiet, Peter van Oyen, Pieter Mattelaer, Hans van den Driessche, Wouter Marchand, Vincent De Ruyter, Johan Braeckman, Luc Merckx, Ovadia Bar-Moshé, Pascal Maisonobe, Patrick Cabri
Publikováno v:
Drugs-Real World Outcomes
BACKGROUND: Androgen deprivation therapy has been associated with worsened body image in prostate cancer patients. Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afbf921f34e3132e0de0dec5bed5f07f
https://doi.org/10.1007/s40801-016-0074-5
https://doi.org/10.1007/s40801-016-0074-5
Autor:
Jozef Ampe, Christophe Ghysel, Bram De Laere, Steven Van Laere, Lucien Hoekx, Wim Demey, Piet Van Kerckhove, Daan De Maeseneer, Karen Fransis, Peter Van Oyen, Piet Ost, Willem Lybaert, Els Everaert, Michiel Strijbos, Jean Vandebroek, Alain Bols, Luc Dirix, Barbara Brouwers, Dirk Schrijvers, Gert Van den Eynden
Publikováno v:
Journal of Clinical Oncology. 35:5049-5049
5049 Background: A heterogeneous landscape of patients with metastatic castration-resistant prostate cancer (mCRPC) exists in current clinical practice. We investigated the prognostic value of CTC enumeration and dynamics, in the context of second-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f45365e5fc09e32adb373021fe1eb3
https://doi.org/10.1200/jco.2017.35.15_suppl.5049
https://doi.org/10.1200/jco.2017.35.15_suppl.5049